RevMed with huge news for pancreatic cancer (daraxonrasib). The headline is hard to ignore 👀 • Median OS 13.2 vs 6.7 months • HR ~0.4 📉 • Activity across KRAS variants (not just G12C) • Manageable safety If that signal is real, this isn’t incremental. It changes how we think about KRAS. But—caveat applies ⚠️ This is a press release! PR as a rule is rosier than real data. Still… an OS HR like that gets your attention. Feels like we may be moving from mutation-specific inhibition → broader KRAS control. That’s the difference between niche utility and something that touches CRC, pancreas, lung… everything we see. Now we wait for the data behind the headline. @TheGutOncLab @OncoAlert @Onco_Nexus ir.revmed.com/news-releases/…

When I started out, I thought my job would mostly be clinic and clinical trials. Take care of patients. Design studies. Move the needle a little at a time. Fast forward a few years and somehow that has turned into running trials, building enterprise AI tools, obsessing over biomarkers, arguing about liver-directed therapy… and still sitting in clinic every week having very real, very human conversations. Somewhere along the way it started to feel like there was more to say. GI oncology is moving fast. Data drops weekly. Technology is creeping into everything. We’re learning in real time. And a lot of the nuance never makes it into a manuscript. It definitely doesn’t fit in a tweet. We wanted a place to unpack that. So we made one. The Gut Onc Lab 🎙️ It’s a new podcast where we talk about GI cancers, trials, translational science, tech, and what actually happens when those ideas meet real patients. Sharing a teaser clip below 👇 If you’re interested in colorectal cancer, pancreas, liver mets, ctDNA, immunotherapy, or how AI is starting to weave its way into oncology… I think you’ll like what’s coming. oncologynexus.com/podcast/gu… @OncoAlert @TheGutOncLab @Onco_Nexus